Numerous clinical studies have shown the beneficial therapeutic effects of DPP-4 inhibitors in type 1 diabetes, where they decreased prandial insulin dose and total daily dose (TDD) of insulin [6, 7], inhibited glucagon secretion [8] and reduced blood glucose levels [9]. The gene discussed is INS; the disease is type 1 diabetes mellitus.